Lixte Biotechnology Holdings, Inc.
$3.44
▼
-0.49%
2026-04-21 07:54:01
lixte.com
NCM: LIXT
Explore Lixte Biotechnology Holdings, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$39.91 M
Current Price
$3.44
52W High / Low
$6.26 / $0.64
Stock P/E
—
Book Value
$0.9
Dividend Yield
—
ROCE
-431.9%
ROE
-1.02%
Face Value
—
EPS
$-1.26
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
3
Beta
0.95
Debt / Equity
9.44
Current Ratio
3.88
Quick Ratio
3.88
Forward P/E
—
Price / Sales
—
Enterprise Value
$34.39 M
EV / EBITDA
—
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | CytoMed Therapeutics Limited | $1.02 | — | $12.07 M | — | -33.09% | -50.28% | $3.68 / $0.73 | $0.43 |
| 2. | Matinas BioPharma Holdings, Inc. | $0.55 | — | $3.52 M | — | -202.13% | -1.67% | $3.09 / $0.48 | $1.09 |
| 3. | Arbutus Biopharma Corporation | $4.6 | — | $899.2 M | — | -30.53% | -38.52% | $5.1 / $2.94 | $0.4 |
| 4. | Benitec Biopharma Inc. | $13.99 | — | $483.71 M | — | -42.71% | -33.5% | $17.15 / $9.85 | $5.47 |
| 5. | AN2 Therapeutics, Inc. | $3.62 | — | $129.78 M | — | -71.59% | -52.14% | $6.91 / $1 | $1.94 |
| 6. | Aldeyra Therapeutics, Inc. | $1.78 | — | $105.92 M | — | -79.69% | -58.73% | $6.17 / $1.07 | $0.74 |
| 7. | eXoZymes, Inc. | $10.66 | — | $89.88 M | — | -220.6% | -1.33% | $18.4 / $7.08 | $0.4 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -1.82 M | -1.8 M | -0.77 M | -0.71 M | -0.61 M | — |
| Net Profit | -2.54 M | -1.98 M | -0.78 M | -0.71 M | -0.62 M | — |
| EPS in Rs | -0.22 | -0.17 | -0.07 | -0.06 | -0.05 | -0.44 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -5.11 M | -3.57 M | -5.09 M | -6.31 M |
| Net Profit | -6.01 M | -3.59 M | -5.09 M | -6.31 M |
| EPS in Rs | -0.52 | -0.31 | -0.44 | -0.54 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 12.73 M | 1.15 M | 4.31 M | 5.56 M |
| Total Liabilities | 1.77 M | 0.32 M | 0.31 M | 0.4 M |
| Equity | 9.66 M | 0.83 M | 3.99 M | 5.17 M |
| Current Assets | 5.18 M | 1.15 M | 4.31 M | 5.56 M |
| Current Liabilities | 1.33 M | 0.32 M | 0.31 M | 0.4 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -3.07 M | -3.16 M | -4.29 M | -4.61 M |
| Investing CF | -3.17 M | 0 M | — | — |
| Financing CF | 10.31 M | 0 M | 3.14 M | 5.14 M |
| Free CF | -3.07 M | -3.16 M | -4.29 M | -4.61 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 29.51% | 19.41% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-06-05 | 1:0.1 |